The West Midlands Academic Health Science Network leads, catalyses and drives co-operation, collaboration and productivity between academia, industry, health and care providers and commissioners, and citizens, and accelerates the adoption of innovation to generate continuous improvement in the region’s health and wealth.
This will be achieved in a collaborative environment in which member organisations are mutually supportive and in which the technology-rich West Midlands’ life sciences community is fully integrated and generating additional investment. Innovation will be spread at scale and pace regionally, nationally and internationally. WMAHSN, its partners and the public will celebrate the region’s success as a centre for innovation, health and wealth and as the first digitally-enabled health economy in England. The improved generation and adoption of innovation will benefit the economy by giving the region’s academic institutions and life sciences industry a competitive advantage.
NHS Clinical Commissioners (NHSCC) and the AHSNs have launched a new joint report that shows how collaboration between clinical commissioning groups (CCGs) and AHSNs is bringing positive benefits to local patients and populations. In their continuing efforts to achieve the… Read More
As the Patient Safety Collaboratives programme moves into its third year, WMAHSN staff joined colleagues from across the country to celebrate successes with a major event at the Emirates Stadium in London on Tuesday 23 May. Also launched at the… Read More
65 million urine specimens delivered annually to the NHS, of which up to 73% will be unreliable. Here, Giovanna Forte, CEO and Co-Founder of Forte Medical, discusses the company's Peezy Midstream urine collection device with George Kennedy CBE, President of the Association of British Healthcare Industries. Peezy Midstream is one of the innovations on Meridian, our health innovation exchange. Peezy Midstream improves urine specimen quality to 98.5% accuracy, delivering right-first-time preventative medicine, patient dignity and huge long-term cost savings across the clinical pathways. Forte Medical can demonstrate potential national direct savings of around £30m and efficiency savings of over £1.2bn from this device.